Literature DB >> 16251342

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

J Li, C R Rayner, R L Nation, R Deans, R Boots, N Widdecombe, A Douglas, J Lipman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251342      PMCID： PMC1280168          DOI： 10.1128/AAC.49.11.4814-4815.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography.

Authors:  J Li; R W Milne; R L Nation; J D Turnidge; K Coulthard; D W Johnson
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-09-25

3.  Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard; Jason Valentine
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels.

Authors:  N J Goodwin; E A Friedman
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

5.  Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.

Authors:  David Berlana; J M Llop; E Fort; M B Badia; R Jódar
Journal:  Am J Health Syst Pharm       Date:  2005-01-01       Impact factor: 2.637

6.  Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin.

Authors:  Argyris Michalopoulos; Sofia K Kasiakou; Evangelos S Rosmarakis; Matthew E Falagas
Journal:  Scand J Infect Dis       Date:  2005

7.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079

9.  Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  J Antimicrob Chemother       Date:  2004-03-24       Impact factor: 5.790

10.  Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.

Authors:  Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos
Journal:  Crit Care       Date:  2003-07-28       Impact factor: 9.097
View more
  43 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

2.  Colistin dosing and nephrotoxicity in a large community teaching hospital.

Authors:  C Andrew Deryke; Amanda J Crawford; Nizam Uddin; Mark R Wallace
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

Review 4.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

5.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 7.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 9.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 10.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.